Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1255-1262

  Mahajan, Raman ^a   Das, Pradeep ^b   Isaakidis, Petros ^a   Sunyoto, Temmy ^a   Sagili, Karuna D ^c   Lima, Marla Angeles ^a   Mitra, Gaurab ^a   Kumar, Deepak ^a   Pandey, Krishna ^b   Van Geertruyden, Jean Pierre ^d   Boelaert, Marleen ^e   Burza, Sakib ^a,e  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Rajendra Medical Research Institute   (India)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

AmBisome; Combination treatment; HIV; Miltefosine; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE; AMPHOTERICIN B; PHOSPHORYLCHOLINE;

ADOLESCENT; ADULT; ANTIRETROVIRAL COMBINATION THERAPY; ANTIVIRAL THERAPY; ARTICLE; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; HIV INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIASIS, VISCERAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PARASITOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE; VIROLOGY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMPHOTERICIN B; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943258575     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ530     Document Type: Article

References (22)

1. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999; 12:62-8.
2. Department of AIDS Control, NACO, Ministry of Health and family Welfare Government of India. State HIV Epidemic Fact Sheets July 2014. Available at: http://www.naco.gov.in/upload/2014mslns/STATEHIVEPIDEMICFACTSHEET.pdf. Accessed 10 March 2015.
3. Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis 2014; 59:552-5.
4. WHO Control of the Leishmaniasis. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis, Geneva, 22-26 March 2010. Geneva: 2010: 1-186.
5. Olivier M, Badaro R, Medrano FJ, Moreno J. The pathogenesis of leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 2003; 97(suppl 1):79-98.
6. Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 2013; 26:1-9.
7. Burza S, Sinha PK, Mahajan R, et al. Five-year field results and longterm effectiveness of 20 mg/kg liposomal amphotericin B (ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 2014; 8:e2603.
8. Burza S, Mahajan R, Sinha PK, et al. Visceral leishmaniasis and HIV coinfection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis 2014; 8:e3053.
9. Sinha PK, van Griensven J, Pandey K, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011; 53:e91-8.
10. Ritmeijer K, ter Horst R, Chane S, et al. Limited effectiveness of highdose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011; 53:e152-8.
11. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334, 59, table of contents.
12. Ritmeijer K. Old and new treatments for HIV/VL co-infection. In: Proceedings of the Fifth World Leishmaniasis Congress, 13-17 May 2013; Porto de Galhinas, Brazil, 2013.
13. Cunningham J, Hasker E, Das P, et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 2012; 55:1312-9.
14. Department of AIDS Control, NACO, Ministry of Health and family Welfare Government of India. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents: May 2013. Available at: http://www.naco.gov.in/upload/Policies&Guidelines/AntiretroviralTherapy GuidelinesforHIV-InfectedAdultsandAdolescents.pdf. Accessed 9 July 2015.
15. Tropical Disease Research and World Health Organization. Indicators for monitoring and evaluation of the Kala-azar elimination programme, August 2010, Bangladesh, India and Nepal, 2010. Available at: http://www.who.int/tdr/publications/documents/kala-azar-indicators.pdf. Accessed 9 July 2015.
16. van Griensven J, Ritmeijer K, Lynen L, Diro E. Visceral leishmaniasis as an AIDS defining condition: towards consistency across WHO guidelines. PLoS Negl Trop Dis 2014; 8:e2916.
17. Blankers M, Koeter MW, Schippers GM. Missing data approaches in eHealth research: simulation study and a tutorial for nonmathematically inclined researchers. J Med Internet Res 2010; 12:e54.
18. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702-9.
19. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 2011; 5:e1153.
20. Drugs for Neglected Disease Initiative. A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine. Available at: http://fieldresearch.msf.org/msf/bitstream/10144/332058/1/1a-DNDiProtocol HIVVLFINALVersion121129.pdf. Accessed 9 July 2015.
21. Purkait B, Kumar A, Nandi N, et al. Mechanism of amphotericin B resistance in clinical isolates of leishmania donovani. Antimicrob Agents Chemother 2012; 56:1031-41.
22. Minutes of firstmeeting of working group on HIV and kala-azar in India. Available at http://nvbdcp.gov.in/Doc/HIV-KA-treatment-minutes-ofmeetingSept. 2014.pdf. Accessed 9 July 2015.